acting on hepatocytes, glucagon promotes (and insulin inhibits) camp-dependent mechanisms that down-regulate lipogenic enzymes and cholesterol synthesis, while up-regulating hepatic ldl receptors and production of the igf-i antagonist igfbp-1.